Acetylon receives U.S. patent for ACY-1215 to treat multiple myeloma

Acetylon Pharmaceuticals Inc. today announced that it has been granted U.S. Patent 8,148,526 by the United States Patent and Trademark Office (USPTO). This patent contains fundamental composition of matter claims covering the Company's selective HDAC6 inhibitor, ACY-1215^TM, which is currently being investigated in human clinical trials for the treatment of multiple myeloma. Acetylon also announced that Chief Executive Officer, Walter Ogier, will present an overview of the Company at 1:30 PM today at the 19^th Annual Future Leaders in the Biotech Industry Conference, hosted by BioCentury and Thomson Reuters at the Millennium Broadway Hotel & Conference Center in New York City.    

Acetylon's patent application was granted "prioritized examination" status under the provisions of the new "America Invents Act," signed into law by President Obama in September 2011. The American Invents Act provides for prioritized "fast track" examination of patent applications that satisfy specific limitations regarding the number and type of examined claims.

"Given the widespread interest in the development of selective histone deacetylase (HDAC) inhibitors, it is important for Acetylon to demonstrate that we have unique, patentable drug candidates within a competitive composition-of-matter field of intellectual property." commented Walter Ogier, Chief Executive Officer of Acetylon. "The rapid issuance of this important US patent and our presentation this afternoon at Future Leaders reinforces Acetylon's position as a leader in the development of selective HDAC inhibitors."

"Acquiring U.S. patent protection for ACY-1215 is a major step for Acetylon as the company continues to explore the use of this drug in the treatment of multiple myeloma," stated John H. van Duzer, Ph.D., Vice President of Chemistry and Manufacturing for Acetylon. "We are also continuing to move forward with additional patent applications which claim further compounds similar to ACY-1215 as well as other unique series of molecules."